Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Number of Shares and Votes in Medivir

Medivir
Posted on: 30 Apr 18

STOCKHOLM, April 30, 2018 /PRNewswire/ -- Medivir AB ("Medivir" or the "Company") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed as a result of conversion of all class A shares to class B shares.

Today, the last trading day of the month, there are in total 24,287,818 shares in Medivir, of which 0 are class A shares and 24,287,818 class B shares, totaling 24,287,818 votes.

For further information, please contact:

Christine Lind
CEO
Medivir AB
phone: +46-(0)-8-5468-3100

Erik Björk
CFO
Medivir AB
phone: +46-(0)-72-228-2831

This is information that Medivir AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 30 April 2018.

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.